🩸🔬Today's question!
See the answer and explanation on the next slide.
#MultipleMyeloma #MAIATrial #FrontlineTherapy #Hematology #HemeOnc #ClinicalTrials #CancerTherapy #HEMEHUB #CyBorD #Daratumumab #Lenalidomide #Dexamethasone #DRd #Bortezomib #Thalidomide #Pomalidomide
💊#FDA Approval Update | Belantamab mafodotin-#blmf (#Blenrap)
👉Approved in combination with #bortezomib and #dexamethasone
👉For adult patients with relapsed or refractory #MM, received at least one line of prior therapy
🌟We provide #BelantamabMafodotin, #Belantamab, and #McMMAF for research use.
È ACCADUTO IERI: Mieloma multiplo, Cavo (UniBo): "Importanti nuove combinazioni approvate da Ue" ... LEGGI TUTTO #MielomaMultiplo #BelantamabMafodotin #Bortezomib #Desametasone #Pomalidomide
Monoclonal Gammopathy of Renal Significance (MGRS): Overview, Diagnosis, and Management
#DVP183
#MGRS #KidneyDisease #Nephrology #Amyloidosis #VikaasLLC #LCDD #KidneyBiopsy #Bortezomib #Rituximab #Daratumumab #MGUS #Myeloma #Proteinuria #ESKD
CEPHEUS by Saad Z. Usmani, et al is out
@rahulbanerjeemd.bsky.social
@szusmani.bsky.social
oncodaily.com/science/ceph...
#Bortezomib #Cancer #CD38VR #CEPHEUS #Daratumumab #Dexamethasone #FightAgainstCancer #IMROZ #Oncology #Lenalidomide #MultipleMyeloma #OncoDaily
10-15% of iTTP do not respond to rituximab. Targeting plasma cells can be promising.
In this study, durable responses to bortezomib were registered in 60% of multi-refractory iTTP patients, with mild-to-moderate toxicities.
www.jthjournal.org/article/S153...
#MedSky #HemeSky #TTP #bortezomib
